Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

PMID: 25989270
Journal: BRIT J CANCER
Year: 2015
Reference: Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19.
Impact factor:
Publication type: Paper in international publication
Authors: Cervantes, A; Ciardiello, F; Jego, V; Laffranchi, B; Macarulla, T; Martinelli, E; Prenen, H; Rosello, S; Tabernero, J; Tejpar, S et al.
DOI: 10.1038/bjc.2015.144

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

PMID: 25840972
Journal: CLINICAL CANCER RESEARCH
Year: 2015
Reference: Clin Cancer Res. 2015 Jul 15;21(14):3160-9. doi: 10.1158/1078-0432.CCR-14-3262. Epub 2015 Apr 3.
Impact factor: 8.722
Publication type: Clinical Trials
Authors: Awan, Farrukh T, Jiang, Jason, Brown, Jennifer R, Davids, Matthew S, Rodon, Jordi, Abrisqueta, Pau, Kasar, Siddha N, Lager, Joanne, Egile, Coumaran et al.
DOI: 10.1158/1078-0432.CCR-14-3262

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

PMID: 25840972
Journal: CLIN CANCER RES
Year: 2015
Reference: Clin Cancer Res. 2015 Jul 15;21(14):3160-9. doi: 10.1158/1078-0432.CCR-14-3262. Epub 2015 Apr 3.
Impact factor:
Publication type: Clinical Trials
Authors: Abrisqueta, Pau; Awan, Farrukh T; Brown, Jennifer R; Davids, Matthew S; Egile, Coumaran; Jiang, Jason; Kasar, Siddha N; Lager, Joanne; Rodon, Jordi et al.
DOI: 10.1158/1078-0432.CCR-14-3262

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.

PMID: 25491381
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2015
Reference: Cancer Chemother Pharmacol. 2015 Feb;75(2):319-24. doi: 10.1007/s00280-014-2641-3. Epub 2014 Dec 10.
Impact factor: 2.769
Publication type: Clinical Trials
Authors: Manzano, J L, Galan, M, Alsina, M, Yuste Izquierdo, A L, Lopez, C, Diaz-Rubio, E, Conde, V, Reboredo, M, Cano, M T, Pachon, V et al.
DOI: 10.1007/s00280-014-2641-3

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.

PMID: 25491381
Journal: CANCER CHEMOTH PHARM
Year: 2015
Reference: Cancer Chemother Pharmacol. 2015 Feb;75(2):319-24. doi: 10.1007/s00280-014-2641-3. Epub 2014 Dec 10.
Impact factor:
Publication type: Clinical Trials
Authors: Alsina, M; Aranda, E; Cano, M T; Conde, V; de Paredes, M L Garcia; Diaz-Rubio, E; Galan, M; Lopez, C; Manzano, J L; Martinez Galan, J et al.
DOI: 10.1007/s00280-014-2641-3

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.

PMID: 26497877
Journal: BREAST CANCER RESEARCH AND TREATMENT
Year: 2015
Reference: Breast Cancer Res Treat. 2015 Nov;154(2):287-97. doi: 10.1007/s10549-015-3615-9. Epub 2015 Oct 24.
Impact factor: 3.94
Publication type: Paper in international publication
Authors: Blackwell, Kimberly, Burris, Howard, Gomez, Patricia, Lynn Henry, N, Isakoff, Steven, Campana, Frank, Gao, Lei, Jiang, Jason, Mace, Sandrine, Tolaney, Sara M et al.
DOI: 10.1007/s10549-015-3615-9

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.

PMID: 26497877
Journal: BREAST CANCER RES TR
Year: 2015
Reference: Breast Cancer Res Treat. 2015 Nov;154(2):287-97. doi: 10.1007/s10549-015-3615-9. Epub 2015 Oct 24.
Impact factor:
Publication type: Paper in international publication
Authors: Blackwell, Kimberly; Burris, Howard; Campana, Frank; Gao, Lei; Gomez, Patricia; Isakoff, Steven; Jiang, Jason; Lynn Henry, N; Mace, Sandrine; Tolaney, Sara M et al.
DOI: 10.1007/s10549-015-3615-9

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.

PMID: 25605862
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2015
Reference: J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892. Epub 2015 Jan 20.
Impact factor: 18.428
Publication type: Paper in international publication
Authors: Kaufman, Peter A, Awada, Ahmad, Twelves, Chris, Yelle, Louise, Perez, Edith A, Velikova, Galina, Olivo, Martin S, He, Yi, Dutcus, Corina E, Cortes, Javier et al.
DOI: 10.1200/JCO.2013.52.4892

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.

PMID: 25605862
Journal: J CLIN ONCOL
Year: 2015
Reference: J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892. Epub 2015 Jan 20.
Impact factor:
Publication type: Paper in international publication
Authors: Awada, Ahmad; Cortes, Javier; Dutcus, Corina E; He, Yi; Kaufman, Peter A; Olivo, Martin S; Perez, Edith A; Twelves, Chris; Velikova, Galina; Yelle, Louise et al.
DOI: 10.1200/JCO.2013.52.4892

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

PMID: 25925990
Journal: GYNECOLOGIC ONCOLOGY
Year: 2015
Reference: Gynecol Oncol. 2015 Jul;138(1):18-23. doi: 10.1016/j.ygyno.2015.04.026. Epub 2015 Apr 26.
Impact factor: 3.774
Publication type: Paper in international publication
Authors: McMeekin, Scott, Dizon, Don, Barter, James, Scambia, Giovanni, Manzyuk, Lyudmila, Lisyanskaya, Alla, Oaknin, Ana, Ringuette, Sarah, Mukhopadhyay, Pralay, Rosenberg, Julie et al.
DOI: 10.1016/j.ygyno.2015.04.026

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

PMID: 25925990
Journal: GYNECOL ONCOL
Year: 2015
Reference: Gynecol Oncol. 2015 Jul;138(1):18-23. doi: 10.1016/j.ygyno.2015.04.026. Epub 2015 Apr 26.
Impact factor:
Publication type: Paper in international publication
Authors: Barter, James; Dizon, Don; Lisyanskaya, Alla; Manzyuk, Lyudmila; McMeekin, Scott; Mukhopadhyay, Pralay; Oaknin, Ana; Ringuette, Sarah; Rosenberg, Julie; Scambia, Giovanni et al.
DOI: 10.1016/j.ygyno.2015.04.026

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

PMID: 26673577
Journal: Trials
Year: 2015
Reference: Trials. 2015 Dec 16;16:575. doi: 10.1186/s13063-015-1101-7.
Impact factor: 1.731
Publication type: Clinical Trials
Authors: Harbeck, Nadia, Barton, Debora, Renschler, Markus F, Beck, Robert M, Yardley, Denise A, Brufsky, Adam, Coleman, Robert E, Conte, Pierfranco F, Cortes, Javier, Gluck, Stefan et al.
DOI: 10.1186/s13063-015-1101-7

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

PMID: 26673577
Journal: TRIALS
Year: 2015
Reference: Trials. 2015 Dec 16;16:575. doi: 10.1186/s13063-015-1101-7.
Impact factor:
Publication type: Clinical Trials
Authors: Barton, Debora; Beck, Robert M; Brufsky, Adam; Coleman, Robert E; Conte, Pierfranco F; Cortes, Javier; Gluck, Stefan; Harbeck, Nadia; Ko, Amy; Nabholtz, Jean-Mark A et al.
DOI: 10.1186/s13063-015-1101-7

Phenotype consequences of myophosphorylase dysfunction: insights from the McArdle mouse model.

PMID: 25873271
Journal: JOURNAL OF PHYSIOLOGY-LONDON
Year: 2015
Reference: J Physiol. 2015 Jun 15;593(12):2693-706. doi: 10.1113/JP270085. Epub 2015 May 18.
Impact factor: 5.037
Publication type: Paper in international publication
Authors: Blanco-Grau, Albert, Lucia, Alejandro, Martin, Miguel Angel, Arenas, Joaquin, Marti, Ramon, Andreu, Antoni L, Pinos, Tomas, de Luna, Noemi, Brull, Astrid et al.
DOI: 10.1113/JP270085

Phenotype consequences of myophosphorylase dysfunction: insights from the McArdle mouse model.

PMID: 25873271
Journal: J PHYSIOL-LONDON
Year: 2015
Reference: J Physiol. 2015 Jun 15;593(12):2693-706. doi: 10.1113/JP270085. Epub 2015 May 18.
Impact factor:
Publication type: Paper in international publication
Authors: Andreu, Antoni L; Arenas, Joaquin; Blanco-Grau, Albert; Brull, Astrid; de Luna, Noemi; Lucia, Alejandro; Marti, Ramon; Martin, Miguel Angel; Pinos, Tomas et al.
DOI: 10.1113/JP270085

Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry.

PMID: 25038238
Journal: ANNALS OF THE RHEUMATIC DISEASES
Year: 2015
Reference: Ann Rheum Dis. 2015 Nov;74(11):2043-9. doi: 10.1136/annrheumdis-2013-204991. Epub 2014 Jul 18.
Impact factor: 10.377
Publication type: Paper in international publication
Authors: Bader-Meunier, B, Levy, R, Gerard, L, Kuemmerle-Deschner, J, Lachmann, H J, Kone-Paut, I, Cantarini, L, Woo, P, Naselli, A, Ozen, S et al.
DOI: 10.1136/annrheumdis-2013-204991

Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry.

PMID: 25038238
Journal: ANN RHEUM DIS
Year: 2015
Reference: Ann Rheum Dis. 2015 Nov;74(11):2043-9. doi: 10.1136/annrheumdis-2013-204991. Epub 2014 Jul 18.
Impact factor:
Publication type: Paper in international publication
Authors: Al-Mayouf, S M; Bader-Meunier, B; Cantarini, L; Frenkel, J; Gattorno, M; Gerard, L; Hofer, M; Insalaco, A; Kone-Paut, I; Kuemmerle-Deschner, J et al.
DOI: 10.1136/annrheumdis-2013-204991

Phone and Video-Based Modalities of Central Blinded Adjudication of Modified Rankin Scores in an Endovascular Stroke Trial.

PMID: 26542697
Journal: STROKE
Year: 2015
Reference: Stroke. 2015 Dec;46(12):3405-10. doi: 10.1161/STROKEAHA.115.010909. Epub 2015 Nov 5.
Impact factor: 5.723
Publication type: Paper in international publication
Authors: Lopez-Cancio, Elena, Salvat, Merce, Cerda, Neus, Jimenez, Marta, Codas, Javier, Llull, Laura, Boned, Sandra, Cano, Luis M, Lara, Blanca, Molina, Carlos et al.
DOI: 10.1161/STROKEAHA.115.010909

Phone and Video-Based Modalities of Central Blinded Adjudication of Modified Rankin Scores in an Endovascular Stroke Trial.

PMID: 26542697
Journal: STROKE
Year: 2015
Reference: Stroke. 2015 Dec;46(12):3405-10. doi: 10.1161/STROKEAHA.115.010909. Epub 2015 Nov 5.
Impact factor:
Publication type: Paper in international publication
Authors: Boned, Sandra; Cano, Luis M; Cerda, Neus; Cobo, Erik; Codas, Javier; Davalos, Antoni; Jimenez, Marta; Jovin, Tudor G; Lara, Blanca; Llull, Laura et al.
DOI: 10.1161/STROKEAHA.115.010909

Phospholipid profile of amniotic fluid in ovine model of congenital diaphragmatic hernia (CDH): the effect of fetal tracheal occlusion.

PMID: 25625961
Journal: JOURNAL OF PROTEOME RESEARCH
Year: 2015
Reference: J Proteome Res. 2015 Mar 6;14(3):1465-71. doi: 10.1021/pr501120x. Epub 2015 Feb 11.
Impact factor: 4.245
Publication type: Paper in international publication
Authors: Peiro, Jose Luis, Mimmi, Maria Chiara, Ballico, Maurizio, Amoroso, Francesco, Calcaterra, Valeria, Marotta, Mario, Pelizzo, Gloria et al.
DOI: 10.1021/pr501120x

Phospholipid profile of amniotic fluid in ovine model of congenital diaphragmatic hernia (CDH): the effect of fetal tracheal occlusion.

PMID: 25625961
Journal: J PROTEOME RES
Year: 2015
Reference: J Proteome Res. 2015 Mar 6;14(3):1465-71. doi: 10.1021/pr501120x. Epub 2015 Feb 11.
Impact factor:
Publication type: Paper in international publication
Authors: Amoroso, Francesco; Ballico, Maurizio; Calcaterra, Valeria; Marotta, Mario; Mimmi, Maria Chiara; Peiro, Jose Luis; Pelizzo, Gloria et al.
DOI: 10.1021/pr501120x

Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.

PMID: 26502900
Journal: Orphanet Journal of Rare Diseases
Year: 2015
Reference: Orphanet J Rare Dis. 2015 Oct 26;10:138. doi: 10.1186/s13023-015-0358-y.
Impact factor: 3.358
Publication type: Paper in international publication
Authors: Serrano, Mercedes, de Diego, Victor, Muchart, Jordi, Cuadras, Daniel, Felipe, Ana, Macaya, Alfons, Velazquez, Ramon, Poo, M Pilar, Fons, Carmen, O'Callaghan, M Mar et al.
DOI: 10.1186/s13023-015-0358-y

Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.

PMID: 26502900
Journal: ORPHANET J RARE DIS
Year: 2015
Reference: Orphanet J Rare Dis. 2015 Oct 26;10:138. doi: 10.1186/s13023-015-0358-y.
Impact factor:
Publication type: Paper in international publication
Authors: Artuch, Rafael; Boix, Cristina; Briones, Paz; Carratala, Francisco; Cuadras, Daniel; de Diego, Victor; Felipe, Ana; Fons, Carmen; Garcia-Cazorla, Angels; Giros, Marisa et al.
DOI: 10.1186/s13023-015-0358-y

Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches.

PMID: 25923732
Journal: PLoS One
Year: 2015
Reference: PLoS One. 2015 Apr 29;10(4):e0123352. doi: 10.1371/journal.pone.0123352. eCollection 2015.
Impact factor: 3.234
Publication type: Paper in international publication
Authors: Martinez, Alba, Sese, Marta, Losa, Javier Hernandez, Robichaud, Nathaniel, Sonenberg, Nahum, Aasen, Trond, Ramon Y Cajal, Santiago et al.
DOI: 10.1371/journal.pone.0123352

Publications

Publications searcher

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

Phenotype consequences of myophosphorylase dysfunction: insights from the McArdle mouse model.

Phenotype consequences of myophosphorylase dysfunction: insights from the McArdle mouse model.

Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry.

Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry.

Phone and Video-Based Modalities of Central Blinded Adjudication of Modified Rankin Scores in an Endovascular Stroke Trial.

Phone and Video-Based Modalities of Central Blinded Adjudication of Modified Rankin Scores in an Endovascular Stroke Trial.

Phospholipid profile of amniotic fluid in ovine model of congenital diaphragmatic hernia (CDH): the effect of fetal tracheal occlusion.

Phospholipid profile of amniotic fluid in ovine model of congenital diaphragmatic hernia (CDH): the effect of fetal tracheal occlusion.

Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.

Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.

Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches.

Patronage:

Collaborating:

Accreditations: